Skip to main content

Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction /gastric cancer.’

Open
  • Protocol code: CL1-95029-002
  • EudraCT code: No aplica
  • Research group: Biomedical Research in Digestive Tract Tumors
  • Service: Oncology
  • Principal investigator:  Acosta Eyzaguirre, Daniel
  • Pathology: Tumors
  • Phase: Fase I
  • Status: Recruiting volunteers